Editas Medicine Inc
8EM
Company Profile
Business description
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary ene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Contact
11 Hurley Street
CambridgeMA02141
USAT: +1 617 401-9000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
87
Stocks News & Analysis
stocks
AI isn’t an economic moat killer, but it will disrupt industries
How we’re rethinking companies’ competitive advantages in an AI-first world.
stocks
AI lands a blow on some Aussie stocks – yet stands to benefit others
AI is reshaping ASX tech moats - but some are more insulated than others.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,618.20 | 78.40 | -0.90% |
| CAC 40 | 7,726.20 | 60.58 | 0.79% |
| DAX 40 | 22,653.86 | 273.67 | 1.22% |
| Dow JONES (US) | 46,208.47 | 631.00 | 1.38% |
| FTSE 100 | 9,894.15 | 24.18 | -0.24% |
| HKSE | 24,382.47 | 894.85 | -3.54% |
| NASDAQ | 21,946.76 | 299.15 | 1.38% |
| Nikkei 225 | 52,648.28 | 1,132.79 | 2.20% |
| NZX 50 Index | 12,857.89 | 41.83 | -0.32% |
| S&P 500 | 6,581.00 | 74.52 | 1.15% |
| S&P/ASX 200 | 8,424.30 | 80.30 | -0.94% |
| SSE Composite Index | 3,813.28 | 143.77 | -3.63% |